請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52714完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 忻凌偉 | |
| dc.contributor.author | Yu-Chien Cheng | en |
| dc.contributor.author | 鄭榆蒨 | zh_TW |
| dc.date.accessioned | 2021-06-15T16:24:26Z | - |
| dc.date.available | 2020-09-24 | |
| dc.date.copyright | 2015-09-24 | |
| dc.date.issued | 2015 | |
| dc.date.submitted | 2015-08-14 | |
| dc.identifier.citation | 1. Leopoldo, M.; M. Contino; F. Berardi; R. Perrone; N. A. Colabufo. PET radiotracers for imaging P-glycoprotein: the challenge for early diagnosis in AD. Chemmedchem 2014, 9, 38-42. 2. Syvänen, S. and J. Eriksson. Advances in PET imaging of P-glycoprotein function at the blood-brain barrier. ACS Chem. Neurosci. 2013, 4, 225-237. 3. Borst, P.; R. Evers; M. Kool; J. Wijnholds. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer I. 2000, 92, 1295-1302. 4. Miller,P. W.; N. J. Long; R. Vilar; A. D. Gee. Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. Angew. Chem. Int. Edit. 2008, 47, 8998-9033. 5. Bansal, T.; M. Jaggi; R. K Khar; S. Talegaonkar. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J. Pharm. Pharm. Sci. 2009, 12, 46-78. 6. Bankstahl, J. P.; C. Kuntner; A. Abrahim; R. Karch; J. Stanek; T. Wanek; W. Wadsak; K. Kletter; M. Müller; W. Löscher; O. Langer. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J. Nucl. Med. 2008, 49, 1328-1335. 7. Bart, J.; E. C. F. Dijkers; T. D. Wegman; E. G. E. de Vries; W. T. A. van der Graaf; H. J. M. Groen; W. Vaalburg; A. T. M. Willemsen; N. H. Hendrikse. New positron emission tomography tracer [11C]carvedilol reveals P-glycoprotein modulation kinetics. Brit. J. Pharmacol. 2005, 145, 1045-1051. 8. Bauer, F.; C. Kuntner; J. P. Bankstahl; T. Wanek; M. Bankstahl; J. Stanek; S. Mairinger; B. Dörner; W. Löscher; M. Müller; T. Erker; O. Langer. Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorgan. Med. Chem. 2010, 18, 5489-5497. 9. Bauer, M.; R. Karch; M. Zeitlingerl; J. Stanek; C. Philippe; W. Wadsak; M. Mitterhauser; W. Jäger; H. Haslacher; M. Müller; O. Langer. Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier. J. Nucl. Med. 2013, 54, 1181-1187. 10. Bergmann, R.; P. Brust; M. Scheunemann; H. J. Pietzsch; S. Seifert; F. Roux; B. Johannsen. Assessment of the in vitro and in vivo properties of a 99mTc-labeled inhibitor of the multidrug resistant gene product P-glycoprotein. Nucl. Med. Biol. 2000, 27, 135-141. 11. De Bruyne, S.; L. Wyffels; L. Moerman; J. Sambre; N. A. Colabufo; F. Berardi; R. Perrone; F. de Vos. Radiosynthesis and in vivo evaluation of [11C]MC80 for P-glycoprotein imaging. Bioorgan. Med. Chem. 2010, 18, 6489-6495. 12. Dörner, B.; C. Kuntner; J. P. Bankstahl; T. Wanek; M. Bankstahl; J. Stanek; J. Müllauer; F. Bauer; S. Mairinger; W. Löscher; D. W. Miller; P. Chiba; M. Müller; T. Erker; O. Langer. Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein. Bioorgan. Med. Chem. 2011, 19, 2190-2198. 13. Fellner, M.; W. Dillenburg; H. G. Buchholz; N. Bausbacher; M. Schreckenberger; F. Renz; F. Rösch; O. Thews. Assessing P-glycoprotein (Pgp) activity in vivo utilizing 68Ga-schiff base complexes. Mol. Imaging Biol. 2011, 13, 985-994. 14. Kawamura, K.; T. Yamasaki; F. Konno; J. Yui; A. Hatori; K. Yanamoto; H. Wakizaka; M. Takei; Y. Kimura; T. Fukumura; M. R. Zhang. Evaluation of limiting brain penetration related to P-glycoprotein and breast cancer resistance protein using [11C]GF120918 by PET in mice. Mol. Imaging Biol. 2011, 13, 152-160. 15. Kawamura, K.; T. Yamasaki; J. Yui; A. Hatori; F. Konno; K. Kumata; T. Irie; T. Fukumura; K. Suzuki; I. Kanno; M. R. Zhang. In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [11C]gefitinib. Nucl. Med. Biol. 2009, 36, 239-246. 16. Kuntner, C.; J. P. Bankstahl; M. Bankstahl; J. Stanek; T. Wanek; B. Dörner; F. Bauer; S. Mairinger; T. Erker; M. Müller; W. Löscher; O. Langer. Assessing cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor [11C]substrate scans. Neuroimage 2010, 52, S116. 17. Kuntner, C.; J. P. Bankstahl; M. Bankstahl; J. Stanek; T. Wanek; G. Stundner; R. Karch; R. Brauner; M. Meier; X. Ding; M. Mueller; W. Löscher; O. Langer. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)- [11C]verapamil PET. Eur. J. Nucl. Med. Mol. I. 2010, 37, 942-953. 18. Kreisl, W. C.; J.-S. Liow; N. Kimura; N. Seneca; S. S. Zoghbi; C. L. Morse; P. Herscovitch; V. W. Pike; R. B. Innis. P-Glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J. Nucl. Med. 2010, 51, 559-566. 19. La Fougère, C.; G. Böning; H. Bartmarm; B. Wängler; S. Nowak; T. Just; E. Wagner; P. Winter; A. Rominger; S. Förster; F. J. Gildehaus; P. Rosa-Neto; L. Minuzzi; P. Bartenstein; H. Potschka; P. Cumming. Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar. Neuroimage 2010, 49, 1406-1415. 20. Lee, Y. J.; J. Maeda; H. Kusuhara; T. Okauchi; M. Inaji; Y. Nagai; S. Obayashi; R. Nakao; K. Suzuki; Y. Sugiyama; T. Suhara. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil. J. pharmacol. Exp. Ther. 2006, 316, 647-653. 21. Liow, J. S.; S. Lu; J. A. McCarron; J. Hong; J. L. Musachio; V. W. Pike; R. B. Innis; S. S. Zoghbi. Effect of a P-glycoprotein inhibitor, cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY. Synapse 2007, 61, 96-105. 22. Liow, J. S.; W. Kreisl; S. S. Zoghbi; N. Lazarova; N. Seneca; R. L. Gladding; A. Taku; P. Herscovitch; V. W. Pike; R. B. Innis. P-Glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys. J. Nucl. Med. 2009, 50, 108-115. 23. Luurtsema, G.; C. F. M. Molthoff; A. D. Windhorst; J. W. Smit; H. Keizer; R. Boellaard; A. A. Lammertsma; E. J. F. Franssen. (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl. Med. Biol. 2003, 30, 747-751. 24. Luurtsema, G.; R. C. Schuit; R. P. Klok; J. Verbeek; J. E. Leysen; A. A. Lammertsma; A. D. Windhorst. Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl. Med. Biol. 2009, 36, 643-649. 25. Mairinger, S.; T. Wanek; C. Kuntner; Y. Doenmez; S. Strommer; J. Stanek; E. Capparelli; P. Chiba; M. Müller; N. A. Colabufo; O. Langer. Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [11C]MC113. Nucl. Med. Biol. 2012, 39, 1219-1225. 26. Márián, T.; L. Balkay; G. Szabó; Z. T. Krasznai; Z. Hernádi; L. Galuska; J. Szabó-Péli; O. Ésik; L. Trón; Z. Krasznai. Biphasic accumulation kinetics of [99mTc]-hexakis-2-methoxyisobutyl isonitrile in tumour cells and its modulation by lipophilic P-glycoprotein ligands. Eur. J. Pharm. Sci. 2005, 25, 201-209. 27. Moerman, L.; C. Dumolyn; P. Boon; F. de Vos. The influence of mass of [11C]-laniquidar and [11C]-N-desmethyl-loperamide on P-glycoprotein blockage at the blood-brain barrier. Nucl. Med. Biol. 2012, 39, 121-125. 28. Muellauer, J.; R. Karch; J. P. Bankstahl; M. Bankstahl; J. Stanek; T. Wanek; S. Mairinger; M. Müller; W. Löscher; O. Langer; C. Kuntner. Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats. Nucl. Med. Biol. 2013, 40, 755-763. 29. Piel, M.; U. Schmitt; N. Bausbacher; H. G. Buchholz; G. Gründer; C. Hiemke; F. Rösch. Evaluation of P-glycoprotein (abcb1a/b) modulation of [18F]fallypride in microPET imaging studies. Neuropharmacology 2014, 84, 152-158. 30. Römermann, K.; T. Wanek; M. Bankstahl; J. P. Bankstahl; M. Fedrowitz; M. Mueller; W. Löscher; C. Kuntner; O. Langer. (R)-[11C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP. Nucl. Med. Biol. 2013, 40, 873-878. 31. Seneca, N.; S. S. Zoghbi; J. S. Liow; W. Kreisl; P. Herscovitch; K. Jenko; R. L. Gladding; A. Taku; V. W. Pike; R. B. Innis. Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein. J. Nucl. Med. 2009, 50, 807-813. 32. Seo, S.; E. Hatano; T. Higashi; A. Nakajima; Y. Nakamoto; M. Tada; N. Tamaki; K. Iwaisako; A. Mori; R. Doi; I. Kai; S. Uemoto. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery 2008, 143, 769-777. 33. Sharma, V.; A. Beatty; S. P. Wey; J. Dahlheimer; C. M. Pica; C. L. Crankshaw; L. Bass; M. A. Green; M. J. Welch; D. Piwnica-Worms. Novel gallium(III) complexes transported by MDR1 P-glycoprotein: potential PET imaging agents for probing P-glycoprotein-mediated transport activity in vivo. Chem. Biol. 2000, 7, 335-343. 34. Syvänen, S.; V. Russmann; J. Verbeek; J. Eriksson; M. Labots; C. Zellinger; N. Seeger; R. Schuit; M. Rongen; R. van Kooij; A. D. Windhorst; A. A. Lammertsma; E. C. de Lange; R. A. Voskuyl; M. Koepp; H. Potschka. [11C]quinidine and [11C]laniquidar PET imaging in a chronic rodent epilepsy model: Impact of epilepsy and drug-responsiveness. Nucl. Med. Biol. 2013, 40, 764-775. 35. Thews, O.; W. Dillenburg; M. Fellner; H. G. Buchholz; N. Bausbacher; M. Schreckenberger; F. Rösch. Activation of P-glycoprotein (Pgp)-mediated drug efflux by extracellular acidosis: in vivo imaging with 68Ga-labelled PET tracer. Eur. J. Nucl. Med. Mol. I. 2010, 37, 1935-1942. 36. Tournier, N.; S. Cisternino; M. A. Peyronneau; S. Goutal; F. Dolle; J. M. Scherrmann; M. Bottlaender; W. Saba; H. Valette. Discrepancies in the P-glycoprotein-mediated transport of 18F-MPPF: a pharmacokinetic study in mice and non-human primates. Pharm. Res. 2012, 29, 2468-2476. 37. Wanek, T.; C. Kuntner; J. P. Bankstahl; M. Bankstahl; J. Stanek; M. Sauberer; S. Mairinger; S. Strommer; V. Wacheck; W. Löscher; T. Erker; M. Müller; O. Langer. A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)- [11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. Eur. J. Nucl. Med. Mol. I. 2012, 39, 149-159. 38. Yamasaki, T.; M. Fujinaga; K. Kawamura; A. Hatori; J. Yui; N. Nengaki; M. Ogawa; Y. Yoshida; H. Wakizaka; K. Yanamoto; T. Fukumura; M. R. Zhang. Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography. Nucl. Med. Biol. 2011, 38, 707-714. 39. Yu, C.; W. Wan; B. Zhang; S. Deng; T. C. Yen; Y. Wu. Evaluation of the relationship between [18F]FDG and P-glycoprotein expression: an experimental study. Nucl. Med. Biol. 2012, 39, 671-678. 40. Zoghbi, S. S.; J. S. Liow; F. Yasuno; J. Hong; E. Tuan; N. Lazarova; R. L. Gladding; V. W. Pike; R. B. Innis. 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J. Nucl. Med. 2008, 49, 649-656. 41. 高碧鴻，國立臺灣大學醫學院藥學研究所碩士論文，96年7月，設計與合成具潛力用於正子斷層掃描的腫瘤造影劑。 42. 劉惠賢，國立臺灣大學醫學院藥學研究所碩士論文，98年12月，合成有潛力作為正子斷層掃描腫瘤造影劑的氟取代蒽醌類化合物。 43. Mitoxantrone Hydrochloride, USP 29, 2006, 1446-1447. 44. Klok, R. P.; P. J. Klein; J. D. M. Herscheid; A. D. Windhorst. Synthesis of N-(3-[18F]Fluoropropyl)-2-carbomethoxy-3-(4-iodophenyl)nortropane([18F]FP--CIT). J. Labelled Compd. Rad. 2006; 49, 77-89. 45. Bourdier, T.; I. Greguric; P. Roselt; T. Jackson; J. Faragalla; A. Katsifis. Fully automated one-pot radiosynthesis of O-(2-[18F]fluoroethyl)-L-tyrosine on the TracerLab FXFN module. Nucl. Med. Biol. 2011, 38, 645-651. 46. Bao, X. and D. Liu. Retracted: Radiosynthesis of 18F-labeled N-desmethyl-loperamide analogues for prospective molecular imaging radiotracers. Tetrahedron Lett. 2013, 54, 1412-1415. 47. Miyachi, H.; H. Kiyota; H. Uchiki; M. Segawa. Synthesis and antimuscarinic activity of a series of 4-(1-imidazolyl)-2,2-diphenylbutyramides: discovery of potent and subtype-selective antimuscarinic agents. Bioorgan. Med. Chem. 1999, 7, 1151-1161. 48. Hsin, L. W.; L. T. Chang; R. B. Rothman; C. M. Dersch; A. E. Jacobson; K. C. Rice. Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters. J. Med. Chem. 2008, 51, 2795-2806. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52714 | - |
| dc.description.abstract | The purpose of this research is to develop a novel PET imaging agent for the study of P-glycoprotein (P-gp) function. A series of fluoroalkyl-aminoanthraquinone derivatives was designed and synthesized based on the skeleton of mitoxantrone (MX) and ametantrone (AT). After pharmacological studies, compound 10 was chosen as the target compound, and compounds 5 and 8 were designed and synthesized as precursors for 18F-radiolabeling. Initially, precursor 5 was easily decomposed under basic condition, but using tetrabutylammonium bicarbonate instead of commonly used base, such as potassium carbonate and potassium oxalate, heating at 100oC for 5 minutes, and then hydrolysis with 2 N hydrochloric acid at 100oC for 5 minutes to yield enough [18F]10 for animal study with microPET. In addition to the purity of precursor, radiochemical yield (RCY) increased from 0.02% to 3.3% when the equivalent of precursor increased from 4 | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T16:24:26Z (GMT). No. of bitstreams: 1 ntu-104-R02423019-1.pdf: 18437786 bytes, checksum: 9f55281b71cc023cd8156311c3b0672c (MD5) Previous issue date: 2015 | en |
| dc.description.tableofcontents | 誌謝…………………………………………………………… i 中文摘要………………………………………………………ii Abstract……………………………………………………… iii Abbreviation………………………………………………… v Content………………………………………………………… vii List of Figure…………………………………………… viii List of Tables……………………………………………… ix List of Schemes…………………………………………… x Chapter 1 Introduction…………………………………1 1.1 P-glycoprotein and Multidrug Resistance…………… 1 1.2 Positron Emission Tomography and Radiotracers for P-glycoprotein………... 2 1.3 Mitoxantrone Analogue……………………………………………………… 16 1.4 Previous Study in Our Laboratory…………………………………………… 16 1.5 Desmethyl-Loperamide Analogue…………………………………………… 18 1.6 Research Goal………………………………………………………………... 19 Chapter 2 Result and Discussion…………………………………… 21 2.1 Fluorination of Compound 6………………………………………………… 21 2.2 Radiolabeling of Compound 1………………………………………………. 29 2.3 Synthesis of Compound 19…………………………………………………... 67 Chapter 3 Conclusion………………………………………………………………69 Chapter 4 Experimental Section……………………………………………. 70 4.1 Commercial Reagents and Solvents…………………………………………. 70 4.2 Dried Reagents and Solvents………………………………………………… 73 4.3 Instrument and Methods……………………………………………………... 74 4.4 Procedures and Analytic Data……………………………………………... 77 Reference………………………………………………………………………………… 86 Appendix…………………………………………………………………………………. 94 | |
| dc.language.iso | en | |
| dc.title | 氟十八標記滲透性醣蛋白分子探針作為新穎正子斷層掃描藥物的研究 | zh_TW |
| dc.title | Study of 18F-labeled P-glycoprotein Molecular Probes as Novel Positron Emission Tomography Imaging Agents | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 103-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 陳基旺,梁碧惠,王光昭,黃雅瑤 | |
| dc.subject.keyword | 氟十八,滲透性醣蛋白,分子探針,正子斷層掃描,造影劑, | zh_TW |
| dc.subject.keyword | 18F,P-glycoprotein,Molecular Probes,Positron Emission Tomography,Imaging Agents, | en |
| dc.relation.page | 108 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2015-08-14 | |
| dc.contributor.author-college | 藥學專業學院 | zh_TW |
| dc.contributor.author-dept | 藥學研究所 | zh_TW |
| 顯示於系所單位： | 藥學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-104-1.pdf 目前未授權公開取用 | 18.01 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。